DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Brimonidine (Brimonidine Tartrate Ophthalmic) - Summary

 
 



BRIMONIDINE SUMMARY

BRIMONIDINE TARTRATE OPHTHALMIC SOLUTION

Brimonidine tartrate ophthalmic solution 0.2% is a relatively selective alpha-2 adrenergic agonist for ophthalmic use.

Brimonidine tartrate ophthalmic solution is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The IOP lowering efficacy of Brimonidine tartrate ophthalmic solution diminishes over time in some patients. This loss of effect appears with a variable time of onset in each patient and should be closely monitored.


See all Brimonidine indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Brimonidine ( Ophthalmic)

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial. [2014]
hypertension... CONCLUSIONS: Bimatoprost/timolol PF demonstrated non-inferiority and equivalence

Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. [2014]
PARTICIPANTS: A total of 588 adult subjects with dry eye disease... CONCLUSIONS: Lifitegrast ophthalmic solution 5.0% significantly reduced corneal

Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. [2013]
for multiple sclerosis (MS)... CONCLUSIONS: Fingolimod 0.5 mg is associated with a low incidence of ME in MS

Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical trial. [2013]
Allergic conjunctivitis (AC) affects an estimated 20% of the population in the Western world, with a large fraction suffering due to seasonal or perennial allergen exposures. Bepotastine besilate ophthalmic solution (BBOS) 1.5%, a dual-acting histamine (H(1)) receptor antagonist and mast cell stabilizer, is indicated for itching associated with AC...

Progesterone increases resistance of ophthalmic and central retinal arteries in climacteric women. [2013]
compared to placebo, using transorbital ultrasound with Doppler velocimetry... CONCLUSIONS: Our results demonstrate the existence of a progestogenic

more studies >>

Clinical Trials Related to Brimonidine ( Ophthalmic)

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension [Completed]
This study evaluates the safety and efficacy of brimonidine 0. 2%/timolol 0. 5% fixed combination ophthalmic solution compared with concurrent brimonidine 0. 2% and timolol ophthalmic solutions

Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs [Completed]
The purpose of this study is to compare the efficacy of brimonidine Purite, dorzolamide, and brinzolamide in reducing intraocular pressure when added to prostaglandin analog therapy (bimatoprost, latanoprost, or travoprost) in patients with glaucoma or ocular hypertension.

A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2% [Recruiting]

Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension [Recruiting]
A multi-center, double-masked, randomized parallel group efficacy and safety study of brinzolamide 1% /brimonidine 0. 2% fixed combination compared to brinzolamide 1% and to brimonidine 0. 2% in patients with open-angle glaucoma or ocular hypertension.

Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension [Recruiting]
This study will evaluate the safety and efficacy of brimonidine tartrate/timolol fixed combination compared with brimonidine tartrate and timolol in patients with glaucoma or ocular hypertension who do not respond well to topical beta blockers.

more trials >>


Page last updated: 2014-11-30

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014